CVS and Walgreens, the two largest drugstore chains in the country, have faced increased competition from superstores and online platforms in recent years. To adapt, both chains are optimizing their brick-and-mortar footprints – and Walgreens is going private following its recent acquisition by Sycamore Partners.
We took a look at the two chains’ visit performance to see what lies ahead for each.
Pharmacies Rightsizing Right
CVS and Walgreens command a major portion of drugstore visits nationwide – and their foot traffic data sheds light on how each is weathering heightened competition. CVS, which consolidated its fleet between 2022 and 2024, saw both overall visits (+0.6%) and average visits per location (+2.9%) elevated YoY in Q4 2024, suggesting that these store closures have helped bolster the chain.
Walgreens, which also closed a significant number of stores over the past two years, saw overall foot traffic lag slightly throughout 2024. However, average visits per location to the chain were up in all but one quarter of the year, suggesting that Walgreen’s rightsizing moves are having a positive impact on the chain, directing more traffic to higher-performing locations.
Visits in the New Year
These patterns held into 2025, with CVS enjoying elevated YoY visits in all weeks analyzed, while Walgreens visits remained, for the most part, slightly below 2024 levels. Walgreens recently announced a definitive agreement to be acquired by private equity firm Sycamore Partners, and while the impact of this deal remains to be seen, it could create opportunities for innovation and strategic transformation.
Gaining Visit Share
CVS and Walmart are major players in the pharmacy space, controlling the lion’s share of offline pharmacy visits (excluding general and grocery retailers with on-site pharmacies such as Walmart and Kroger.) And even as the two chains have reduced their footprints, their overall market presence has expanded – perhaps a reflection of the broader challenges facing smaller pharmacy operators.
Between Q1 2023 and Q4 2024, the share of visits to drugstore and pharmacy retailers attributed to CVS increased from 41.9% to 44.0%, while Walgreens’ share grew modestly from 49.2% to 50.4%. Meanwhile, the share of visits to smaller chains declined from 8.9% to 5.5%. This indicates that CVS’s growing visit share has not come at the expense of Walgreens – underscoring both chains’ resilience and growth potential in the face of sector-wide headwinds.
Changes for CVS
CVS closed hundreds of stores between 2022 and 2024 as it sought to refine its retail strategy – and now, the drugstore seems to be ready for its next move. The chain announced the rollout of about a dozen small-format stores, set to open throughout 2025. These stores will stock more of the essentials – cold medicine, first-aid care – and offer pharmacy services, while eschewing some of the traditional drugstore offerings like greeting cards and groceries.
And exploring CBSA-level visitation patterns at CVS suggests that this move may indeed be giving consumers what they want – especially in certain areas of the country. In 2024, short visits to CVS (i.e. those lasting less than ten minutes) increased YoY in many CBSAs nationwide, but some regions, like the Northeast, experienced stronger short visit growth than others. As CVS plans out its small-format expansion, focusing on regions with strong interest in short visits – where consumers may be particularly interested in an efficient shopping experience at a scaled-down location – could help it capture even more market share while improving customer convenience.
Prescription for Growth
CVS and Walgreens have faced their fair share of challenges in recent years, but both are adapting to stay competitive. New leadership and store formats may help them better serve customers and navigate the shifting retail pharmacy market.
Will the segment continue to adapt to a changing retail environment? Visit Placer.ai to find out.
.svg)